🇺🇸 FDA
Patent

US 11421010

T cells expressing membrane-anchored IL-12 for the treatment of cancer

granted A61KA61K2239/38A61K2239/50

Quick answer

US patent 11421010 (T cells expressing membrane-anchored IL-12 for the treatment of cancer) held by The Board of Regents of the University of Texas System expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
34
CPC classes
A61K, A61K2239/38, A61K2239/50, A61K2239/55, A61K31/675